TruthArchive.ai - Related Video Feed

A viewer asks if the proteins from the vaccine enter the bloodstream. The speaker explains that the mRNA blueprint for the protein is given, which is then translated into the protein in the muscle cells. The protein may enter the tissue and possibly trace amounts may enter the blood, but it is not measurable. The reaction occurs in the muscle, the corresponding defense cells, lymph nodes, and minimally in the blood. The speaker concludes that they have reached an agreement on the topic.

A viewer asks if the proteins from the vaccine enter the bloodstream. The speaker explains that the mRNA blueprint for the protein is given, which is then translated into the protein in the muscle cells. The protein may enter the tissue and possibly trace amounts may enter the blood, but it is not measurable. The reaction occurs in the muscle, the corresponding defense cells, lymph nodes, and minimally in the blood. The speaker concludes that they have reached an agreement on the topic.

A viewer asks if the proteins from the vaccine enter the bloodstream. The speaker explains that the mRNA blueprint for the protein is given, which is then translated into the protein in the muscle cells. The protein may enter the tissue and possibly trace amounts may enter the blood, but it is not measurable. The reaction occurs in the muscle, the corresponding defense cells, lymph nodes, and minimally in the blood. The speaker concludes that they have reached the desired agreement.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

Speaker 0 describes a highly significant and controversial issue surrounding human papillomavirus (HPV) vaccines, including Gardasil and Cervarix, and reports that lawsuits are occurring worldwide. In Japan, there have been major lawsuits with hundreds of plaintiffs, including young women and girls, though the fundamental problem, according to the speaker, centers on contamination with DNA impurities. The speaker states that from the early days of the Ministry of Health, Labour and Welfare in Japan, the core issue has been the contamination with DNA impurities in vaccines, and that this problem had already become clear by 2012 in a widely cited paper. The speaker explains that by 2012, a paper described the DNA contamination in Gardasil-related vaccines, specifically noting residual DNA fragments from HPV types 16 and 18 associated with the vaccine’s aluminum adjuvant particles. The claim is that vaccine samples contained residual HPV DNA fragments that were directly bound to aluminum adjuvant particles, and that PCR tests confirmed these DNA fragments were identical to the HPV sequences described in the paper. The speaker emphasizes that researchers around the world—doctors and researchers listening to women and girls’ voices—noticed unusual, severe post-vaccination symptoms in children and young women, and saw potential links between these symptoms and the residual HPV DNA attached to adjuvants. The testimony references samples gathered from multiple countries (Australia, Bulgaria, France, India, New Zealand, Poland, Russia, Spain, and the United States) and asserts that nearly all of the Gardasil/HPV vaccine lots examined contained residual HPV DNA attached to aluminum adjuvant particles. The speaker mentions that in the specific investigation, sixteen samples of Gardasil-4 contained residual HPV DNA fragments bound to aluminum adjuvant particles, and that all samples tested via PCR showed the same DNA sequence as described in the 2012 paper. The speaker claims that in 2014, the vaccine program for cervical cancer halted in Japan, and that the subsequent attention brought this issue to light publicly. The discussion attributes the major role to a Japanese expert, Ishii Ken (Ishii-sensei), described as a leading figure in Japan’s vaccine adverse-event research. The speaker recounts that, in the years around 2012–2014, efforts involved international collaboration with HR/HSA, FDA, and others, although logistical obstacles caused delays. The speaker notes that in 2012, 16 vaccine packages were distributed in nine countries for examination and that contamination persisted in all samples. They credit Japan with acting as a global relay for disseminating information about DNA contamination and its potential health implications. Further, the speaker references a broader context: the later emergence of literature discussing how DNA contamination might relate to adverse neurological or systemic symptoms, and the evolution of guidelines on acceptable residual DNA in vaccines. The discussion mentions that WHO and FDA guidelines permit changing permissible DNA limits over time, with higher thresholds introduced for manufacturing and regulatory purposes, raising questions about what constitutes safety and what is permissible in drug development. The dialogue closes with Speaker 1 alluding to the seriousness of the issue, noting deaths in the context of messenger-type vaccines and subsequent debates about vaccine safety, while acknowledging that those opposed to this view are also active.

Speaker 0: I read the sequence and it's high-resolution. Speaker 1: It may seem low at first, but it's understandable. Speaker 0: This is written in a loop. Speaker 1: This is the genetic sequence of the spike protein. The issue is that the model RNA has a sequence that surprised me. We need to design it a bit. It contains part of the sequence SB4T, which is necessary for gene expression. The problem is that it is found in a virus that has negative effects. Also, there is another problem with this sequence. The DNA that has been transferred so far becomes more susceptible to mutation. It's a problematic point. Speaker 1: So, this SB4T sequence is also included in the promoter of this SB method, which allows it to migrate to the nucleus. Speaker 0: This is quite famous. Speaker 1: Yes, it is. The issue is that it has no relation to the process of synthesizing the messenger RNA. Speaker 0: Why did they keep the promoter sequence in the SB4T that has nothing to do with the camera's perspective in the messenger RNA synthesis process?

The speaker asks the regulator if they would request sponsors to conduct intensive analysis to anticipate any immunogenicity issues when reviewing dossiers with extensive optimization. The regulator responds that they understand the burden and do not require specific assays, but they do ask for protein characterization and perform an in silico analysis. If they identify any red flags, they may request further analysis. They generally ask for standard characterization and may increase scrutiny if adverse events specific to optimized proteins arise. The conversation ends with a thank you.

The symposium revolves around the science and safety implications of Replicating/Replicon vaccines and broader RNA vaccine platforms, with a sequence of expert presentations and reactions from the panel. -荒川博 presents the central premise that Replicon vaccines (replicating or self-amplifying RNA vaccines) raise unique safety and biosafety concerns beyond traditional mRNA vaccines. He frames the discussion around the idea that these vaccines “increase and mutate” within the host, potentially evolving in ways that could affect humans and populations. He references specific real-world events and case observations, including severe vascular events and tissue damage in some vaccine recipients, as motivation to scrutinize this technology carefully. -荒川 emphasizes that Replicon vaccines differ from conventional mRNA vaccines by embedding replicative machinery so that the RNA self-amplifies inside cells. He explains that, unlike ordinary mRNA vaccines, replication can produce more copies of the RNA and additional viral proteins, potentially leading to unexpected immune and biological consequences. He notes that the Alpha virus replicase used in some designs is designed to enable replication and increased antigen production, but that high mutation and recombination potential could yield variants or new properties. -藤本、藤田（参加者は複数） and others discuss the science of replication in viruses, highlighting the Central Dogma nuances. They describe that normally DNA → RNA → protein is the standard flow, but some viruses (RNA viruses and certain retroviruses) can reverse or bypass parts of this flow (RNA to DNA in retroviruses; RNA to RNA replication in some RNA viruses). This provides a conceptual basis for why replicating vaccines could, in principle, generate abnormal replication dynamics or new variants. -コロナウイルスRNAワクチンの議論では、Repliconの増殖と変異率の高さ、組換えの可能性、体内拡散の可能性を挙げて、「増えると変わる」性質が人の体内でどう影響するかが核心テーマとして挙げられます。アルファウイルス由来のレプリカーゼを使う場合、修復機能が不完全なRNAの増殖過程で、予想外の抗原変異を引き起こすリスクがあるとの指摘が出てきます。 -リスクの具体例として、ウイルスの殻（エンベロープ）とエクソソームを介した分布、自己拡散型ワクチンによる体内の遺伝子素材の取り込み、さらには他の人へ感染・伝播するアウトブレークの可能性、という仮説的懸念が提示されます。レプリコンワクチンは「空の遺伝子を抗原遺伝子に置き換えた陰性空間を持つウイルス」という説明が繰り返され、組換え・遺伝子交換・逆転など、従来のDNA・RNA動態の外に出る事象が起こり得ると議論されます。 -一部のスピーカーは、日本での試験・臨床・規制の動きを取り上げ、FDA/国内基準値を超えるDNA混入、SV40プロモーター混入の報告など、製品レベルでの懸念を指摘します。ケビン・マッカーシー氏の分析紹介では、日本市場で使われているファイザー社のコロナワクチンにDNA混入の痕跡があったこと、SV40プロモーター混入の可能性が指摘され、脂質ナノ粒子を通じた細胞内へのDNA／エクソンの取り込みリスクが懸念事項として挙げられます。これにより、RNAワクチンのフォーマットが終わるのではなく、プラットフォーム自体が拡大・進化する過程で新たなリスクを生む可能性を示唆します。 -IGG4関連疾患の急増とコロナワクチンの関連を例示する報告を紹介。IGG-4抗体が高値となり、多様な臓器炎症を引き起こす病態が観察され、ウイルス感染・ワクチン接種と免疫抑制・過剰免疫の連携が臨床で見られるケースの存在が議論されました。これにより、免疫の過剰反応・異常免疫を招く可能性があるとの懸念が示唆されました。 -ウイルス学・免疫学の専門家は、Repliconワクチンの「増殖・変異・組換えの三拍子」が、長期的・広範な公衆衛生影響をもたらし得る点を強調します。従来のウイルスワクチンの枠組みを超え、自己拡散・他者伝播・遺伝子汚染の可能性を定量的に評価する必要があると主張します。 -議論は、Repliconの潜在的リスクと実利を天秤にかけるもので、現時点で「安全」と断定できないという結論に至る場面が多くありました。実臨床での結果を長期観察で検証し、エビデンスに基づく判断を求める声が複数の speaker から出ました。 -最後に、メディア・一般市民への啓蒙の喚起と、透明性の高い情報提供、そして次世代ワクチン開発の安全性を担保するための厳格な規制・評価の重要性が強調されました。現状の科学的理解には限界があり、今後も公衆衛生への影響を見据えた厳密な検証が不可欠であるとの結論が共有されました。 overall, the event centers on the scientific basis, potential risks, and regulatory considerations of Replicon vaccines, contrasted with traditional mRNA vaccines, with emphasis on mutation, recombination, potential horizontal spread, DNA contamination concerns, immune dysregulation (including IGG4-associated phenomena), and the need for rigorous, transparent evaluation before broad deployment.

Many are surprised to learn that the vaccines did not undergo traditional clinical trials. Initially, they were manufactured using PCR for 44,000 people, but when scaling up, the process was deemed too costly and was replaced with DNA from E. Coli, which also introduced endotoxins. In pharmaceutical manufacturing, the process is crucial; changing it typically requires new trials. The EMA requested a new trial with 252 patients, but the data was never provided, and it was considered too late since vaccinations had already begun. Thus, the rationale for conducting the trial became irrelevant.

Using more c and g in biotechnology translates proteins quicker, evading the immune system. However, altering the folding structure by increasing GC content in Pfizer's and Moderna's drugs poses risks. Computer models show significant differences in folding between the drugs and the natural virus, potentially leading to prion disease concerns. These modifications make the drugs more hazardous than the original virus.

The speaker questions whether the mRNA complexes in the vaccines meet the definition of genetically modified organisms (GMOs) under Australian legislation. The response states that mRNA technology is not gene therapy and does not alter human DNA. The speaker insists on knowing if the possibility was examined, but the response reiterates that the vaccines are not GMOs. The speaker then asks if Pfizer has notified its underwriters about potential litigation, but the response is uncertain and requests further investigation. Another speaker presents a document from Pfizer's website stating that gene technology includes a process used in the COVID vaccine. The committee agrees to review the document and suggests sending additional questions to Pfizer.

Pfizer's own document, the American Society of Gene and Cell Therapy, and the TGA all acknowledge that mRNA vaccines are a form of gene therapy. The speaker questions why the mRNA vaccine wasn't tested for genotoxicity and why the Office of Genetic Therapeutics didn't consider it as gene technology. The response states that the TGA is responsible for approving the vaccine and the question of genotoxicity should be directed to them. It is clarified that the mRNA vaccines were imported into Australia and not manufactured there. The speaker disagrees, citing Pfizer's admission that transfection is part of gene therapy. The response disagrees with the speaker's interpretation.

Speaker 0 lays out a detailed critique of how the transition from process one to process two allegedly occurred, arguing that process one was deliberately structured to “cook the books” so that regulators would see nothing in their assays, while the real material of concern—DNA contaminants, including plasmids and RNA/DNA hybrids—would only be detectable in process two. Key points - The shift from process one to process two is alleged to be planned from the start. The assays used were designed “not to find things,” and the trial was set up in process one with the expectation that process two would ultimately be used, exposing a premeditated sequence of actions. - Ten nanogram limit and copy number. The ten nanogram figure is framed as a limited hangout: the real concern is molarity and copy number of DNA molecules, not weight. Naked-DNA half-lives are short, but lipid nanoparticles (LNPs) protect DNA, altering degradation and persistence. The origin of the 10 ng limit traces to Sheng Fowler and Keith Patten’s work, which emphasized copy number (molarity) rather than weight, particularly for small fragments and plasmids. The argument is that 10 ng can correspond to vastly different copy numbers depending on fragment size; smaller fragments dramatically increase copy number and potential integration ends. - Spike vs. CAN gene targeting. In process one, spike sequences are amplified, then RNA is generated via IVT, and residual DNA is monitored using a CAN gene target. The CAN assay is described as a decoy that would not detect post-amplification products; spike post-amplification would be abundant, but the CAN assay would show little or nothing. In process two, E. coli replication of the entire plasmid would introduce CAN sequences, yet regulators were still steered to look at CAN rather than spike, masking true residual DNA. - Assay design and regulatory deception. The EMA/EMAs documents and related papers show an RT-PCR setup that amplifies spike RNA to confirm expression while also using CAN primers that would not detect post-amplification plasmid content. A key accusation is that the regulators were given an assay that cannot detect the relevant post-amplification material, while an assay for spike exists but is not reported or used. - DNA vs. RNA measurement challenges. qPCR is argued to be ill-suited for this purpose due to fragmentation and the mismatch between input weight and actual molecule count. Fragmentation from DNase treatment is nonrandom: can (CAN) regions are hyper-fragmented, spike regions less so, causing disproportionate detectability depending on primer design and amplicon length. This yields underestimation of the true DNA content when relying on CAN-targeted PCR. - Enzymatic treatment and measurement implications. DNase I degrades CAN more efficiently than spike, particularly when DNA is in a DNA/RNA hybrid context post-IVT. Another enzyme (DNase XT) is claimed to better digest RNA-DNA hybrids, moving CT values for CAN and leaving spike detectable. This suggests the choice of enzymes was deliberate to obscure true residual DNA, while spike DNA remains more detectable under alternative assays. - Measurement methods and data interpretation. Fluorometry (e.g., PicoGreen or Ribogreen) is used to measure DNA or RNA doses, but crosstalk and fragmentation complicate interpretation. The speaker argues that fluorometry should be used in conjunction with RNase/DNase treatments and proper controls to distinguish DNA from RNA, and cautions that PCR-based extrapolations can massively overestimate or misrepresent actual DNA content due to fragmentation biases. - Consolidated claim. Across multiple studies and preparations, spike DNA is found at significantly higher levels than CAN DNA (e.g., a hundredfold difference in several datasets). The “can” assay is positioned as a decoy, while spike assays reveal the genuine DNA content and potential for integration, signaling intentional misdirection in regulator briefings. The speaker concludes that the “game of hide the ball” is ongoing: regulators have been misdirected to look for CAN DNA in process one, while the meaningful residual DNA relates to spike-containing sequences post-amplification—yet this is not consistently measured or reported. The overall thrust is that the design of assays and the choice of targets imply intentional deception to obscure true DNA contamination risks, particularly in the transition to process two.

Pfizer's own website acknowledges that gene therapies involve a complex process, including transfection. The American Society of Gene and Cell Therapy defines the COVID mRNA vaccine as a gene therapy that introduces new genetic material temporarily. The TGA's non-clinical report confirms the use of DNA in Pfizer's manufacturing process. The senator questions why the mRNA vaccine wasn't tested for genotoxicity and why the Office of Gene Technology didn't review it as a gene technology. The Gene Technology Regulator states that the TGA is responsible for approving vaccine products and addressing genotoxicity concerns. They clarify that the mRNA vaccines were imported into Australia, and if manufacturing and gene technology were involved, approval would have been required. The Regulator disagrees with the claim that transfection occurs in Australian citizens. The Office of Gene Technology's role is limited to assessing containment and environmental risks.

The regulator is asked if they would require sponsors to conduct intensive analysis to anticipate immunogenicity issues when reviewing dossiers. The regulator responds that they do not ask for such analysis, but rather request sponsors to characterize their proteins and perform in silico analysis. They acknowledge the necessity of codon optimization and only intervene if there are red flags or adverse events related to codon optimized proteins. They emphasize the importance of standard characterization and may increase scrutiny if adverse events arise.

A viewer asks if the proteins from the vaccine enter the bloodstream. The speaker explains that the mRNA blueprint for the protein is given, which is then translated into the protein in the muscle cells. The protein may enter the tissue and possibly trace amounts may enter the blood, but it is not measurable. The reaction occurs in the muscle, the corresponding defense cells, lymph nodes, and minimally in the blood. The speaker concludes that they have reached an agreement on the topic.

The mRNA platform is effective but has a flaw: it can cause autoimmune disorders by producing foreign proteins in cells. The challenge is to target only specific cells and avoid damage to vital organs. The pandemic allowed the emergency use authorization of mRNA vaccines, bypassing safety measures. However, a large portion of the population has already accepted this technology. To address the issue, a solution could be to replace the spike protein with a different protein that doesn't have flaws. But if the problem lies in any foreign protein transcribed by cells, the immune system may still target vital organs.

There is significant DNA contamination found in vaccines, with evidence from multiple researchers in Germany, Japan, and the U.S. Regulatory bodies like the FDA and EMA acknowledge this contamination but downplay its significance, relying on Pfizer's assurances. The clinical trials used cleaner DNA, but the mass-produced vaccines did not undergo the same purification, leading to increased background DNA and endotoxin levels. Regulators received a plasmid map missing crucial annotations, suggesting manipulation. Claims about expired vials and PCR methods used to measure contamination have been challenged, with evidence showing that Moderna's vaccines are cleaner. Regulators are allowing different measurement standards for RNA and DNA, raising concerns about transparency and integrity in the regulatory process.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

Speaker 0 cautions about the long-term side effects of directly modifying a person’s DNA and RNA to encode antibodies. They raise concerns that such genetic or molecular modifications could lead to unforeseen consequences over time, including potential mutations or other risks that might arise downstream as a result of encoding these antibodies.

Current optimization, often considered harmless, can actually have negative effects. Synonymous mutations, which don't change the translated amino acid, have been linked to diseases. The reasons behind this association are often unknown, but factors like translation rate and RNA structure have been implicated. Since many synonymous mutations have been associated with disease, it is possible that codon optimization, which involves multiple substitutions, could also have an impact. This has been extensively reviewed.

A viewer asks if the proteins from the vaccine enter the bloodstream. The speaker explains that the mRNA blueprint for the protein is given, which is then translated into the protein in the muscle cells. The protein may enter the tissue and possibly trace amounts may enter the blood, but it is not measurable. The reaction occurs in the muscle, the corresponding defense cells, lymph nodes, and minimally in the blood. The speaker concludes that they have reached an agreement on the topic.

Current optimization, often considered harmless, has been shown to have effects on disease. Reports indicate that a single synonymous mutation can be linked to disease, although the exact reasons are often unknown. Factors such as translation rate and RNA structure have been implicated in some cases. It is important to note that many synonymous mutations, which do not change the translated amino acid, have been associated with disease. Therefore, if multiple substitutions occur through codon optimization, there is a likelihood of having an impact. This information has been reviewed multiple times.

RNA sequencing of the Moderna vaccine's three prime ends suggests a possible mechanism for RNA persistence: in vivo re-adenylation. The data indicates plasmid DNA contamination despite efforts to reduce it. The data also reveals contamination from other mRNA vaccines in Moderna's pipeline. The speaker suggests that with widespread DNA sequencing capabilities, tolerating incorrect RNA sizes in vaccines is irresponsible. Sequencing before approval would have allowed for a better understanding of low RNA scores before global administration.

Caution about long-term side effects of modifying people’s DNA and RNA to directly encode the ability to produce antibodies, and whether this could cause other mutations or downstream risks.